| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2007PLoSO...2..326B |
| P356 | DOI | 10.1371/JOURNAL.PONE.0000326 |
| P932 | PMC publication ID | 1828617 |
| P698 | PubMed publication ID | 17389917 |
| P5875 | ResearchGate publication ID | 51374869 |
| P50 | author | Carsten Watzl | Q40172272 |
| P2093 | author name string | Rauf Bhat | |
| P2860 | cites work | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 |
| Biology of natural killer cells | Q29619728 | ||
| Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. | Q30477822 | ||
| Stepwise cytoskeletal polarization as a series of checkpoints in innate but not adaptive cytolytic killing | Q30478310 | ||
| Natural killer cells in antiviral defense: function and regulation by innate cytokines | Q33652468 | ||
| Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy | Q34175390 | ||
| The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal | Q35136000 | ||
| Monoclonal antibodies as therapeutic agents for cancer | Q35761687 | ||
| From the bench to the bedside: ways to improve rituximab efficacy. | Q35822517 | ||
| Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion | Q35848493 | ||
| Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. | Q36403556 | ||
| The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design | Q36547207 | ||
| Regulation of 2B4 (CD244)-mediated NK cell activation by ligand-induced receptor modulation | Q40207266 | ||
| Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response | Q40536409 | ||
| Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset | Q41390529 | ||
| Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. | Q46232762 | ||
| Multiple target cell killing by the cytolytic T lymphocyte and the mechanism of cytotoxicity. | Q54617457 | ||
| Kinetic analysis of target cell destruction by effector T cells. I. Delineation of parameters related to the frequency and lytic efficiency of killer cells | Q67528940 | ||
| Mechanism of cell-mediated cytotoxicity at the single cell level. VIII. Kinetics of lysis of target cells bound by more than one cytotoxic T lymphocyte | Q71006497 | ||
| Delivery of lethal hits by cytotoxic T lymphocytes in multicellular conjugates occurs sequentially but at random times | Q72117607 | ||
| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene | Q77535970 | ||
| Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study | Q80787686 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | e326 | |
| P577 | publication date | 2007-03-28 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies | |
| P478 | volume | 2 |
| Q92239553 | A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer |
| Q27312227 | A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry |
| Q38696214 | A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. |
| Q38704554 | ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody |
| Q38169149 | Activation of Lymphocyte Cytolytic Machinery: Where are We? |
| Q37686302 | An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele |
| Q34819510 | An acidic microenvironment increases NK cell killing of Cryptococcus neoformans and Cryptococcus gattii by enhancing perforin degranulation |
| Q27694769 | Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies |
| Q39521727 | Analysis of transient migration behavior of natural killer cells imaged in situ and in vitro |
| Q60924652 | Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression |
| Q90183818 | Anti-myeloma activity and molecular logic operation by Natural Killer cells in microfluidic droplets |
| Q30432874 | Antigenic modulation and rituximab resistance |
| Q42952399 | Are natural killer cells superior CAR drivers? |
| Q96220333 | CD56 regulates human NK cell cytotoxicity through Pyk2 |
| Q37480221 | CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection |
| Q47970705 | Cd226-/- natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo |
| Q26852411 | Cell biological steps and checkpoints in accessing NK cell cytotoxicity |
| Q38940741 | Ceramide participates in lysosome-mediated cell death induced by type II anti-CD20 monoclonal antibodies |
| Q38666579 | Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy |
| Q38787705 | Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody |
| Q89896570 | Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role |
| Q37370451 | Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer |
| Q35918821 | Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity |
| Q59813521 | Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC |
| Q39869331 | Cryptococcus neoformans directly stimulates perforin production and rearms NK cells for enhanced anticryptococcal microbicidal activity. |
| Q45170030 | Cystatin F Affects Natural Killer Cell Cytotoxicity |
| Q30648415 | Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids |
| Q90734623 | Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors |
| Q90627999 | Emerging insights into human health and NK cell biology from the study of NK cell deficiencies |
| Q27025330 | Emerging role of Natural killer cells in oncolytic virotherapy |
| Q42415560 | Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells |
| Q30421637 | Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients |
| Q60046090 | Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells |
| Q37565077 | Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target |
| Q37378585 | Formation and function of the lytic NK-cell immunological synapse |
| Q34551581 | GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo |
| Q37218249 | Generation of a dual-functioning antitumor immune response in the peritoneal cavity |
| Q91736879 | Harnessing natural killer cells for the treatment of ovarian cancer |
| Q89965508 | High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia |
| Q36386541 | Human NK cell lytic granules and regulation of their exocytosis |
| Q34031624 | Human NK cells differ more in their KIR2DL1-dependent thresholds for HLA-Cw6-mediated inhibition than in their maximal killing capacity |
| Q39700975 | Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. |
| Q39027063 | IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential |
| Q30539057 | Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells |
| Q33754766 | Imaging immune surveillance of individual natural killer cells confined in microwell arrays |
| Q30439017 | Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies |
| Q55284365 | Impedance-based analysis of Natural Killer cell stimulation. |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q39643562 | Intravital Imaging Reveals Distinct Dynamics for Natural Killer and CD8+ T Cells during Tumor Regression |
| Q51538910 | Inverted open microwells for cell trapping, cell aggregate formation and parallel recovery of live cells. |
| Q37996368 | Investigation of NK cell function and their modulation in different malignancies. |
| Q51533224 | Live cell imaging in a micro-array of acoustic traps facilitates quantification of natural killer cell heterogeneity. |
| Q37553914 | Mechanisms and functions for the duration of intercellular contacts made by lymphocytes |
| Q27329179 | Microchip Screening Platform for Single Cell Assessment of NK Cell Cytotoxicity |
| Q58091445 | Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer |
| Q89837486 | Molecular regulation of the plasma membrane-proximal cellular steps involved in NK cell cytolytic function |
| Q34700655 | Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives |
| Q89820688 | NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS |
| Q38245228 | NK Cell Subset Redistribution during the Course of Viral Infections |
| Q41346723 | NK Cells are Activated in Amnestic Mild Cognitive Impairment but not in Mild Alzheimer's Disease Patients |
| Q93023715 | NK cell detachment from target cells is regulated by successful cytotoxicity and influences cytokine production |
| Q102057122 | NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis |
| Q91593420 | NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing |
| Q80189198 | NK cells--from basic research to cancer therapy |
| Q38631020 | NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy |
| Q37503717 | NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus. |
| Q90599493 | Natural Killer Cells Integrate Signals Received from Tumour Interactions and IL2 to Induce Robust and Prolonged Anti-Tumour and Metabolic Responses |
| Q58785734 | Natural Killer Cells: Development, Maturation, and Clinical Utilization |
| Q38542034 | Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. |
| Q37582007 | Natural killer cell cytotoxicity: how do they pull the trigger? |
| Q50204340 | Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy |
| Q38073764 | New views of the human NK cell immunological synapse: recent advances enabled by super- and high-resolution imaging techniques |
| Q37741570 | Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production |
| Q56908538 | Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity |
| Q38758270 | PGC-1α-Dependent Mitochondrial Adaptation Is Necessary to Sustain IL-2-Induced Activities in Human NK Cells. |
| Q46605719 | Perforin is recaptured by natural killer cells following target cells stimulation for cytotoxicity |
| Q58582595 | Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients |
| Q58801325 | Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells |
| Q52643680 | Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency. |
| Q46113809 | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation |
| Q38090984 | Role of inositol phospholipid signaling in natural killer cell biology. |
| Q27318470 | Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor |
| Q58768033 | Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells |
| Q54246661 | Single Degranulations in NK Cells Can Mediate Target Cell Killing. |
| Q36414417 | Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster |
| Q36217155 | Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity |
| Q92304043 | Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions |
| Q40073065 | Termination of the Activating NK Cell Immunological Synapse Is an Active and Regulated Process. |
| Q38831202 | The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas |
| Q39674450 | The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking |
| Q33580163 | The granzyme B-Serpinb9 axis controls the fate of lymphocytes after lysosomal stress. |
| Q38564920 | The multifaceted role of PIP2 in leukocyte biology. |
| Q27312822 | Trypanosoma brucei Co-opts NK Cells to Kill Splenic B2 B Cells |
| Q26999306 | Tumor-primed NK cells: waiting for the green light |
| Q41337940 | Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice. |
| Q29619175 | Up on the tightrope: natural killer cell activation and inhibition |
| Q57300237 | Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies |
| Q42738220 | WF10 stimulates NK cell cytotoxicity by increasing LFA-1-mediated adhesion to tumor cells |
| Q52963700 | WITHDRAWN: Effective suppression of Rituximab-resistant B-cell lymphoma by a comb-like anti-CD20 mAb nanocluster. |
| Q54223897 | Weak vaccinia virus-induced NK cell regulation of CD4 T cells is associated with reduced NK cell differentiation and cytolytic activity. |
Search more.